Clearmind Medicine (CMND) Reports Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Clearmind Medicine Inc. (NASDAQ: CMND) today announced that as…

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration

Preclinical study results demonstrated the combination of SciSparc’s CannAmideā„¢ with Clearmind’s MEAI has the potential to reduce alcohol consumption TEL AVIV, Israel, May 10, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd.…